| Molecular model for neuroendocrine prostate cancer progression R Chen, X Dong, M Gleave BJU international 122 (4), 560-570, 2018 | 59 | 2018 |
| Progesterone receptor in the prostate: A potential suppressor for benign prostatic hyperplasia and prostate cancer RQ Chen, Y Yu, X Dong The Journal of steroid biochemistry and molecular biology 166, 91-96, 2017 | 53 | 2017 |
| Understanding aberrant RNA splicing to facilitate cancer diagnosis and therapy X Dong, R Chen Oncogene 39 (11), 2231-2242, 2020 | 48 | 2020 |
| UGT2B17 expedites progression of castration-resistant prostate cancers by promoting ligand-independent AR signaling H Li, N Xie, R Chen, M Verreault, L Fazli, ME Gleave, O Barbier, X Dong Cancer research 76 (22), 6701-6711, 2016 | 47 | 2016 |
| Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells R Chen, Y Li, R Buttyan, X Dong Oncotarget 8 (49), 84863, 2017 | 34 | 2017 |
| SRRM4 gene expression correlates with neuroendocrine prostate cancer Y Li, Q Zhang, J Lovnicki, R Chen, L Fazli, Y Wang, M Gleave, J Huang, ... The Prostate 79 (1), 96-104, 2019 | 31 | 2019 |
| Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region J Ren, W Yang, J Su, X Ren, R Fazelzad, T Albert, S Habbous, ... International Journal of Cancer 145 (6), 1465-1474, 2019 | 30 | 2019 |
| RNA splicing of the BHC80 gene contributes to neuroendocrine prostate cancer progression Y Li, N Xie, R Chen, AR Lee, J Lovnicki, EA Morrison, L Fazli, Q Zhang, ... European urology 76 (2), 157-166, 2019 | 23 | 2019 |
| Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4 Y Li, R Chen, M Bowden, F Mo, YY Lin, M Gleave, C Collins, X Dong Oncotarget 8 (40), 66878, 2017 | 23 | 2017 |
| Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase‐based therapy H Sibai, R Chen, X Liu, U Falcone, A Schimmer, A Schuh, A Law, ... British Journal of Haematology 191 (5), 748-754, 2020 | 18 | 2020 |
| Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer SX Jiang, RN Walton, K Hueniken, J Baek, A McCartney, C Labbé, ... Cancer medicine 8 (18), 7542-7555, 2019 | 15 | 2019 |
| Loss of nuclear functions of HOXA10 is associated with testicular cancer proliferation R Chen, H Li, Y Li, L Fazli, M Gleave, L Nappi, X Dong Frontiers in Oncology 8, 594, 2018 | 15 | 2018 |
| Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis SWS Chan, E Smith, R Aggarwal, K Balaratnam, RQ Chen, K Hueniken, ... Clinical Lung Cancer 22 (5), 390-407, 2021 | 9 | 2021 |
| HoxA10 and HoxA11 regulate the expression of contraction-associated proteins and contribute to regionalized myometrium phenotypes in women Y Li, H Li, N Xie, R Chen, AR Lee, D Slater, S Lye, X Dong Reproductive Sciences 25, 44-50, 2018 | 7 | 2018 |
| Anticoagulation prophylaxis with weight-adjusted enoxaparin reduces rates of venous thromboembolism in patients with acute lymphoblastic leukemia receiving asparaginase-based … H Sibai, R Chen, X Liu, AD Schimmer, A Schuh, A Law, CJ McNamara, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 5 | 2018 |
| Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult … RQ Chen, EG Atenafu, J Seki, X Liu, S Chan, V Gupta, D Maze, AC Shuh, ... British Journal of Haematology 201 (4), 645-652, 2023 | 3 | 2023 |
| Who Wants to Translate? Evaluation of a Novel Medical Mandarin Education Program for and by Pre-Clerkship Medical Students JS Zhou, RQ Chen, YY Feng, Y Lu, J Nyhof-Young MedEdPublish 9, 262, 2020 | 2 | 2020 |
| Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI … RQ Chen, EC Smith, SWS Chan, K Hueniken, MC Brown, H Majeed, ... Journal of Clinical Oncology 37 (8_suppl), 85-85, 2019 | 2 | 2019 |
| Correction: implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells R Chen, Y Li, R Buttyan, X Dong Oncotarget 9 (51), 29842, 2018 | 2 | 2018 |
| Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report J Sibai, RQ Chen, IA Nabhani, MA Perusini, H Sibai EJHaem 3 (4), 1374-1376, 2022 | 1 | 2022 |
